Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07369089 · ClinicalTrials.gov registry record · Phase 2
Targeting Treatment-Resistant OUD With Ketamine-Assisted Mindfulness Oriented Recovery Enhancement
A Phase 2 study, sponsored by University of California, San Diego.
- Not yet
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
NCT07369089 is a Phase 2 study that has not yet begun recruiting, run by University of California, San Diego. The registered enrollment target is 88 participants.
The verdict
NCT07369089, a Phase 2 study, has not yet begun recruiting, sponsored by University of California, San Diego.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to examine the usefulness of Mindfulness-Oriented Recovery Enhancement combined with Ketamine-Assisted Psychotherapy (KetaMORE) for individuals with opioid use disorder who are receiving medication treatment. The main question it aims to answer is whether individuals with opioid use disorder who receive Mindfulness-Oriented Recovery Enhancement in combination with Ketamine-Assisted Psychotherapy will demonstrate greater reductions in opioid use and craving than individuals who receive Ketamine-Assisted Psychotherapy with a non-mindfulness support group. Participants will be randomly assigned to receive either Mindfulness-Oriented Recovery Enhancement combined with Ketamine-Assisted Psychotherapy or Ketamine-Assisted Psychotherapy combined with a support group control condition. Researchers will compare these groups on days of opioid use, time to first opioid use lapse, craving, and mood, assessed using ecological momentary assessments and standardized measures collected during treatment and follow-up.
Interventions
- DRUG Ketamine
- BEHAVIORAL Mindfulness-Oriented Recovery Enhancement (MORE)
- BEHAVIORAL Support Group
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2026-02 |
| Est. Completion | 2028-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07369089
The ClinicalTrials.gov registry entry for NCT07369089 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ketamine is the first listed.
NCT07369089 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07369089 about?
NCT07369089 is a clinical study titled "Targeting Treatment-Resistant OUD With Ketamine-Assisted Mindfulness Oriented Recovery Enhancement". The goal of this clinical trial is to examine the usefulness of Mindfulness-Oriented Recovery Enhancement combined with Ketamine-Assisted Psychotherapy (KetaMORE) for individuals with opioid use disorder who are receiving medication treatment. The main question it aims to answer is whether individua...
What is the current status of trial NCT07369089?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2026-02. Estimated completion is 2028-04.
What interventions are being tested in trial NCT07369089?
The interventions under investigation include: Ketamine (DRUG), Mindfulness-Oriented Recovery Enhancement (MORE) (BEHAVIORAL), Support Group (BEHAVIORAL).
Who is sponsoring clinical trial NCT07369089?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.